Proprietary Technologies

Paras Biopharmaceuticals Finland Oy has achieved a remarkable "Frugal Innovation". Company has developed cutting edge technologies for scale up production of biosimilars and long therapeutic peptides.

This results into a Very Economical Way to produce biologics APIs (unmatched in the industry).

Paras Biopharmaceuticals Finland Oy Novel Technologies include:

• Diabrid® Technology
• NobleCleav® Technology
• BioMultifold® Technology
• Cytofold StructQuant® Technology

Company’s innovative technology platform, along-with other associated process technologies enables a very high and economical production of biosimilars API’s for scale-up production in the following categories:

• Osteoporosis 
• Rheumatoid Arthritis  
• Metabolic Disorders (Diabetes) and,
• Oncology

Paras Biopharmaceuticals Finland Oy has achieved and has multiple products in the pipeline. Company plans to deliver at least one product API to market each year. Advanced products for scale up production include:

• Long Acting Insulin - Glargine - Global sales 4.2 billion $/year
• Osteoporosis - Teriparatide - Global sales 1.2 billion $/year
• A Rheumatoid Arthritis Product – Global sales 300 million $/year
• An Onclogy Product